<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188379</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1801</org_study_id>
    <secondary_id>2019-002100-41</secondary_id>
    <nct_id>NCT04188379</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate&#xD;
      the efficacy and safety of ARGX-113 in patients with primary ITP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with chronic ITP with a sustained platelet count response defined as achieving platelet counts of at least 50×10E9/L for at least 4 of the 6 visits between week 19 and 24 of the trial.</measure>
    <time_frame>Up to five weeks (between visits 19 and 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of disease control defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10E9/L in the chronic ITP population</measure>
    <time_frame>Up to 24 weeks (treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population (chronic and persistent ITP) with a sustained platelet count response defined as achieving platelet counts of at least 50×10E9/L for at least 4 of the 6 visits between week 19 and 24 of the trial</measure>
    <time_frame>Up to five weeks (between visits 19 and 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of the WHO-classified bleeding events</measure>
    <time_frame>Up to 31 weeks, at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population achieving platelet counts of at least 50 x 10E9/L for at least 6 of the 8 visits between week 17 and 24 of the trial.</measure>
    <time_frame>Up to 7 weeks (between visits 17 and 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>efgartigimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving efgartigimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod</intervention_name>
    <description>Intravenous infusion of efgartigimod</description>
    <arm_group_label>efgartigimod</arm_group_label>
    <other_name>ARGX-113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ability to understand the requirements of the trial, to provide written informed&#xD;
             consent (including consent for the use and disclosure of research-related health&#xD;
             information), and to comply with the trial protocol procedures (including required&#xD;
             trial visits).&#xD;
&#xD;
          -  Male or female patient aged ≥18 years.&#xD;
&#xD;
          -  Confirmed ITP diagnosis, at least 3 months before randomization and according to the&#xD;
             American Society of Hematology Criteria, and no known other etiology for&#xD;
             thrombocytopenia.&#xD;
&#xD;
          -  Diagnosis supported by a response to a prior ITP therapy (other than thrombopoietin&#xD;
             receptor agonists [TPO-RAs]), in the opinion of the investigator.&#xD;
&#xD;
          -  Mean platelet count of &lt;30×10E9/L from 2 counts: 1 platelet count collected during the&#xD;
             screening period and the predose platelet count on the day of randomization (visit 1).&#xD;
&#xD;
          -  At the start of the trial, the patient is either on concurrent ITP treatment(s) and&#xD;
             has received at least 1 prior therapy for ITP in the past, or the patient is not on&#xD;
             treatment for ITP but has received at least 2 prior treatments for ITP. Patients&#xD;
             receiving permitted concurrent ITP treatment(s) at baseline, must have been stable in&#xD;
             dose and frequency for at least 4 weeks prior to randomization.&#xD;
&#xD;
        Permitted concurrent ITP medications include oral corticosteroids, oral immunosuppressants,&#xD;
        dapsone/danazol, fostamatinib, and/or oral TPO-RAs. Patients not receiving concurrent ITP&#xD;
        therapy are also eligible for the trial if they have not received prior ITP therapy for at&#xD;
        least 4 weeks prior to baseline, and 6 months in case of prior ITP therapy with an&#xD;
        anti-CD20 therapy (eg, rituximab).&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at the&#xD;
             screening visit and a negative urine pregnancy test at baseline before trial&#xD;
             medication (infusion) can be administered. Women are considered of childbearing&#xD;
             potential unless they are postmenopausal (defined by continuous amenorrhea) for at&#xD;
             least 1 year with a folliclestimulating hormone (FSH) of &gt;40 IU/L or are surgically&#xD;
             sterilized (ie, women who had a hysterectomy, a bilateral salpingectomy, both ovaries&#xD;
             surgically removed, or have a documented permanent female sterilization procedure&#xD;
             including tubal ligation). Folliclestimulating hormone can be used to confirm&#xD;
             postmenopausal status in amenorrheic patients not on hormonal replacement therapy.&#xD;
&#xD;
          -  Women of childbearing potential should use a highly effective or acceptable method of&#xD;
             contraception during the trial and for 90 days after the last administration of the&#xD;
             IMP. They must be on a stable regimen, for at least 1 month:&#xD;
&#xD;
               -  combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  intravaginal&#xD;
&#xD;
                    -  transdermal&#xD;
&#xD;
               -  progestogen-only hormonal contraception associated with inhibition of ovulation:&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  injectable&#xD;
&#xD;
                    -  implantable&#xD;
&#xD;
               -  intrauterine device (IUD)&#xD;
&#xD;
               -  intrauterine hormone-releasing system&#xD;
&#xD;
               -  bilateral tubal occlusion&#xD;
&#xD;
               -  vasectomized partner (provided that the partner is the sole sexual partner of the&#xD;
                  trial participant and documented aspermia post procedure)&#xD;
&#xD;
               -  continuous abstinence from heterosexual sexual contact. Sexual abstinence is only&#xD;
                  allowable if it is the preferred and usual lifestyle of the patient.&#xD;
&#xD;
        Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not acceptable&#xD;
&#xD;
          -  male or female condom with or without spermicide&#xD;
&#xD;
          -  cap, diaphragm, or sponge with spermicide -Non-sterilized male patients who are&#xD;
             sexually active with a female partner of childbearing potential must use an acceptable&#xD;
             method of contraception, ie, a condom. Male patients practicing true sexual abstinence&#xD;
             (when this is in line with the preferred and usual lifestyle of the participant) can&#xD;
             be included. Sterilized male patients who have had a vasectomy with documented&#xD;
             aspermia post procedure can be included. In addition, male patients are not allowed to&#xD;
             donate sperm during this period from signing of ICF, throughout the duration of the&#xD;
             trial, and for 90 days after the last administration of IMP.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic&#xD;
             lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune&#xD;
             thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.&#xD;
&#xD;
          -  Use of anticoagulants (eg, vitamin K antagonists, direct oral anticoagulants) within 4&#xD;
             weeks prior to randomization.&#xD;
&#xD;
          -  Use of any transfusions within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Use of Ig (IV, subcutaneous, or intramuscular route) or plasmapheresis (PLEX), 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Use of anti-CD20 therapy (eg, rituximab) within 6 months prior to randomization.&#xD;
&#xD;
          -  Use of romiplostim within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Undergone splenectomy less than 4 weeks prior to randomization.&#xD;
&#xD;
          -  Use of any other investigational drug within 3 months or 5 half lives of the drug&#xD;
             (whichever is longer) prior to randomization.&#xD;
&#xD;
          -  Use of monoclonal antibodies or crystallized fragment (Fc) fusion proteins, other than&#xD;
             those previously indicated, within 3 months prior to randomization.&#xD;
&#xD;
          -  At the screening visit, clinically significant laboratory abnormalities as below:&#xD;
&#xD;
             o Hemoglobin ≤9 g/dL.&#xD;
&#xD;
          -  OR - o International normalized ratio &gt;1.5 or activated partial thromboplastin time&#xD;
             &gt;1.5×ULN.&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
             o Total IgG level &lt;6 g/L.&#xD;
&#xD;
          -  Patients who have a history of malignancy, including malignant thymoma, or&#xD;
             myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate&#xD;
             treatment with no evidence of recurrence for ≥3 years before screening. Patients with&#xD;
             completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous&#xD;
             cell carcinoma) or cervical carcinoma in situ would be permitted at any time.&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160&#xD;
             mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments.&#xD;
&#xD;
          -  History of any major thrombotic or embolic event (eg, myocardial infarction, stroke,&#xD;
             pulmonary embolism, deep venous thrombosis) within 12 months prior to randomization.&#xD;
&#xD;
          -  History of coagulopathy or hereditary thrombocytopenia or a family history of&#xD;
             thrombocytopenia.&#xD;
&#xD;
          -  History of a recent or planned major surgery (that involves major organs eg, brain,&#xD;
             heart, lung, liver, bladder, or gastrointestinal tract) within 4 weeks of&#xD;
             randomization.&#xD;
&#xD;
          -  Positive serum test at screening for an active viral infection with any of the&#xD;
             following conditions:&#xD;
&#xD;
               1. Hepatitis B virus (HBV) that is indicative of an acute or chronic infection,&#xD;
                  unless associated with a negative HBV DNA test&#xD;
                  (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf)&#xD;
&#xD;
               2. Hepatitis C virus (HCV) based on HCV-antibody assay (unless associated with a&#xD;
                  negative HCV RNA test)&#xD;
&#xD;
               3. Human immunodeficiency virus (HIV) based on test results that are associated with&#xD;
                  an acquired immunodeficiency syndrome (AIDS)-defining condition or a CD4 count&#xD;
                  ≤200 cells/mm3&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             other than ITP (eg, cardiovascular, pulmonary, hematologic, gastrointestinal,&#xD;
             endocrine, hepatic, renal, neurological, malignancy, infectious diseases, uncontrolled&#xD;
             diabetes) despite appropriate treatments which could put the patient at undue risk.&#xD;
&#xD;
          -  Patients with known medical history of hypersensitivity to any of the ingredients of&#xD;
             the IMP.&#xD;
&#xD;
          -  Patients who previously participated in a clinical trial with efgartigimod and have&#xD;
             received at least 1 administration of the IMP.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Employees of the investigator or trial center, with direct involvement in the proposed&#xD;
             trial or other trials under the direction of that investigator or trial center, as&#xD;
             well as family of the employees or the investigator.&#xD;
&#xD;
          -  Patients who received a live/live-attenuated vaccine within 4 weeks before screening.&#xD;
             The receipt of any inactivated, sub-unit, polysaccharide, or conjugate vaccine at any&#xD;
             time before screening is not considered an exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site 0010038</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010045</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010034</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0010037</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010042</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010046</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010049</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010040</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010041</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0430004</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0430002</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0430003</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320012</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320011</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320015</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320014</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0320020</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0320002</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3590001</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3590002</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200001</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200008</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200006</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4200007</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330019</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330009</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330015</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330018</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330008</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330016</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0330017</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950006</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950007</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950008</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950009</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950011</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950012</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0490010</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0490008</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0490012</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360004</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360006</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360015</name>
      <address>
        <city>Győr</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0360010</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0360014</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390012</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390014</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390020</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390015</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390010</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390011</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390018</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390019</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390021</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390009</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390017</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390016</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810024</name>
      <address>
        <city>Bunkyō-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810015</name>
      <address>
        <city>Hirakata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810010</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810017</name>
      <address>
        <city>Iruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810011</name>
      <address>
        <city>Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810022</name>
      <address>
        <city>Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810018</name>
      <address>
        <city>Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810020</name>
      <address>
        <city>Minato-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810021</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810014</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0810016</name>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810023</name>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810025</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0310006</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0310005</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0310007</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480030</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480015</name>
      <address>
        <city>Brzozów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480010</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480013</name>
      <address>
        <city>Chorzów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480012</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480008</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480011</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480014</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0480026</name>
      <address>
        <city>Nowy Sącz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480016</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0070006</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070007</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070013</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070015</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070012</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0070010</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340006</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340007</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340030</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340009</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340014</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340015</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 0340012</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340013</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340004</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340011</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900002</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900007</name>
      <address>
        <city>Adapazarı</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900003</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900006</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900008</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900015</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900016</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900013</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900004</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900014</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900018</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900005</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900010</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900009</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900017</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900019</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3800022</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 3800006</name>
      <address>
        <city>Mykolayiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0440008</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0440010</name>
      <address>
        <city>Rhyl</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0440012</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0440014</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.argenxitpstudy.com</url>
    <description>Website for patients</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

